Home » Newsletters » BioWorld

BioWorld

Aug. 7, 2003

View Archived Issues

Santarus Reports Success With SAN-05 Phase III In GI Bleeding

Santarus Inc. hit a fairly high hurdle in its SAN-05 Phase III trial, and partially unveiled early positive results. (BioWorld Today) Read More

BioSante Raises $10.3M To Fund Phase III Study Of Estrogen Gel

Latest Model Ebola Virus Vaccine Rescues Monkeys' Lives; People Version Possibly' Two Years Off

Cellegy Gets Cellegesic Back On Track With New Phase III

Correction

Other News To Note

Appointments And Advancements

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 10, 2025.
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Omada, Caris arrivals continue med-tech IPO hot streak
BioWorld MedTech
Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...